European Epidermal Barrier Research Network

European Epidermal Barrier Research Network

European Epidermal Barrier Research Network

European Epidermal Barrier Research Network

Research Focus

  1. The molecular mechanisms of barrier formation and their roles in skin diseases such as Eczema and in skin cancer

  2. Nuclear degradation in keratinocytes

  3. Barrier function in skin-tropic viral infections

Research Focus Picture

Important Publications

  1. Rogerson C, Wotherspoon DJ, Button R, O’Shaughnessy RFL. Akt-1 associated actomyosin remodeling is required for nuclear lamin dispersal and nuclear shrinkage in epidermal terminal differentiation. Cell Death Differ 2021 Jan 18. doi: 10.1038/s41418-020-00712-9. Online ahead of print

  2. Tommasi C, Rogerson C, Depledge DP, Jones M, Naeem AS, Venturini C, Frampton D, Tutill HJ, Way B, Breuer J, O'Shaughnessy RFL. Kallikrein-Mediated Cytokeratin 10 Degradation Is Required for Varicella Zoster Virus Propagation in Skin. J Invest Dermatol. 2020 Apr;140(4):774-784.e11

  3. Papaioannou E, Solanki A, Lau C-I, Yanez DC, Ross S, Virasami A, Ranz I, Ono M, O'Shaughnessy RFL, Crompton T. Sonic Hedgehog-signalling limits chronic dermatitis via Gli2-driven immune regulatory function. J Clin Invest. 2019 Jul 2;129(8):3153-3170

  4. Gutowska-Owsiak D, Bernardino de La Serna G1, Naeem A, Fritzsche M, Podobas EI, Leeming M, Colin-York H, O’Shaughnessy RFL, Eggeling C and Ogg GS. Orchestrated control of filaggrin-actin scaffolds underpins skin barrier formation, Cell Death and Disease 2018 Apr 1;9(4):412

  5. Rogerson C, Bergamaschi D, O’Shaughnessy RFL. Uncovering mechanisms of nuclear degradation in keratinocytes: a paradigm for nuclear degradation in other tissues. Nucleus. 2018 Jan 1;9(1):56-64

  6. Zhu Y, Underwood J, Macmillan D, Shariff L, O’Shaughnessy RFL, Harper JI, Pickard C, Friedman PS, Healy E, Di WL. Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity, Journal of Allergy and Clinical immunology 2017 Nov;140(5):1310-1322

  7. Naeem A, Tommasi C, Cole C, Brown S, Zhu Y, Moffatt M, Cookson B, Harper JI, Di WL, Reinheckel T, Brown S, O’Shaughnessy RFL. A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis. Journal of Allergy and Clinical immunology 2017 Apr;139(4):1228-1241

  8. Akinduro O, Sully K, Chikh A, Robinson DJ, Patel A, McPhail G, Braun K, Philpott MP, Harwood CA, Carolyn Byrne, O'Shaughnessy RFL & Bergamaschi D (Joint Senior Author). Constitutive autophagy and nucleophagy during epidermal development. J Invest Dermatol. 2016 Jul;136(7):1460-70

  9. Naeem AS, Zhu Y, Di WL, Marmiroli S, O'Shaughnessy RFL. AKT1-mediated Lamin A/C degradation is required for nuclear degradation and normal epidermal terminal differentiation. Cell Death Differ. 2015 Dec;22(12):2123-32

  10. Youssef G, Ono M, Brown SJ, Kinsler VA, Sebire NJ, Harper JI, O'Shaughnessy RFL. Identifying a hyperkeratosis signature in autosomal recessive congenital ichthyosis: Mdm2 inhibition prevents hyperkeratosis in a rat ARCI model. J Invest Dermatol. 2014 Mar;134(3):858-861

  11. O’Shaughnessy RFL, Choudhary I and Harper JI. Interleukin-1 alpha blockade prevents hyperkeratosis in an in vitro model of lamellar ichthyosis. Human Molecular Genetics 2010; 19(13): 2594-2605

  12. O’Shaughnessy RFL, Welti JC, Byrne C, AKT-Dependent PP2A activity is required for epidermal barrier formation during late embryonic development. Development 2009. Sep, 136: 3423-3431

  13. O’Shaughnessy RFL, Akgul B, Pfister H, Harwood C and Byrne CR. Cutaneous human papillomaviruses downregulate Akt1 while Akt2 upregulation and activation associates with tumours. Cancer Res. 2007 Sep 1;67(17):1-9

last update: 2021, April